engleski

Lack of Awareness in Managment and Monitoring of Monoclonal Gammopathy of Undetermined Significance (MGUS) in Patients aged 60 years and more in Primary Health Care: Short Communication

Monoclonal gammopathy of unknown significance (MGUS) presents premalignant disorders, associated with a rate of progression to multiple myeloma or a related malignant condition of 1 percent per year or less. This rare condition occurs in approximately 5% of patients over age 65. As it is known, that most of patients in age 60 or more suffer from comorbidity, these patients present a big challenge for general practicionare in order to proper diagnose of MGUS, due to overlapping of symtoms associated with primary disorder. As it is not recommended routine screening for MGUS in the general population, there is lack of awereness of GP, and unclear criteria how to recognise and identify this high-risk cohort. Once, when MGUS is confirmed, the patient should be risk-stratified to determine the need for bone marrow biopsy and to predict the risk of progression to more serious conditions. Even though most patients diagnosed with MGUS will never develop malignant disease, follow-up is needed. Current practice guidelines do not recommend routine screening for MGUS in the general population because of the lack of proven benefit and absence of curative or preventive therapy

Monoclonal gammopathy ; M-protein ; Comorbidity ; Guidelines

nije evidentirano